ID 58717
FullText URL
fulltext.pdf 1.59 MB
Author
Katoh, Norito Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
Ohya, Yukihiro Allergy Center, National Center for Child Health and Development
Ikeda, Masanori Department of Pediatric Acute Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kaken ID publons researchmap
Ebihara, Tamotsu Department of Dermatology, Keio University School of Medicine
Katayama, Ichiro Department of Dermatology, Graduate School of Medicine, Osaka University
Saeki, Hidehisa Department of Dermatology, Graduate School of Medicine, Nihon Medical School
Shimojo, Naoki Department of Pediatrics, Graduate School of Medicine, Chiba University
Tanaka, Akio Department of Dermatology, Hiroshima University Graduate School of Biomedical Sciences
Nakahara, Takeshi Division of Skin Surface Sensing, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
Nagao, Mizuho Division of Clinical Research, National Hospital Organization Mie National Hospital
Hide, Michihiro Department of Dermatology, Hiroshima University Graduate School of Biomedical Sciences
Fujita, Yuji Department of Pediatrics, Graduate School of Medicine, Chiba University
Fujisawa, Takao Division of Allergy, National Hospital Organization Mie National Hospital
Futamura, Masaki Division of Pediatrics, National Hospital Organization Nagoya Medical Center
Masuda, Koji Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
Murota, Hiroyuki Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences
Yamamoto-Hanada, Kiwako Allergy Center, National Center for Child Health and Development
Abstract
Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.
Keywords
Atopic dermatitis
Clinical practice guidelines
Eczema
Evidence-based medicine
Treatment
Published Date
2020-04-04
Publication Title
Allergology International
Volume
volume69
Issue
issue3
Publisher
Elsevier
Start Page
356
End Page
369
ISSN
13238930
NCID
AA11091750
Content Type
Journal Article
language
英語
OAI-PMH Set
岡山大学
Copyright Holders
© 2020 Japanese Society of Allergology. Production and hosting by Elsevier B.V.
File Version
publisher
PubMed ID
DOI
Related Url
IsVersionOf 10.1016/j.alit.2020.02.006
License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Citation
Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020 [published online ahead of print, 2020 Apr 4]. Allergol Int. 2020;S1323-8930(20)30018-6. doi:10.1016/j.alit.2020.02.006
Open Access (Publisher)
OA
Open Archive (publisher)
Non-OpenArchive